RT Journal Article
SR Electronic
T1 Transient Complement Inhibition Promotes a Tumor-Specific Immune Response through the Implication of Natural Killer Cells
JF Cancer Immunology Research
JO Cancer Immunol Res
FD American Association for Cancer Research
SP 200
OP 206
DO 10.1158/2326-6066.CIR-13-0173
VO 2
IS 3
A1 Janelle, Valérie
A1 Langlois, Marie-Pierre
A1 Tarrab, Esther
A1 Lapierre, Pascal
A1 Poliquin, Laurent
A1 Lamarre, Alain
YR 2014
UL http://cancerimmunolres.aacrjournals.org/content/2/3/200.abstract
AB Although the role of the complement system in cancer development has been studied, its involvement in the development of an antitumoral immune response remains poorly understood. Using cobra venom factor (CVF) to inhibit the complement cascade via C3 molecule exhaustion in immunocompetent mice bearing B16gp33 melanoma tumors, we show that transient inhibition of the complement system allowed for the development of a more robust gp33-specific antitumoral CD8+ T-cell response. This immune response proved to be natural killer (NK) dependent, suggesting an interaction of complement proteins with this cellular subset leading to T lymphocyte activation and enhanced cytotoxic T-cell activity against tumor cells. This study demonstrates for the first time the implication of the complement system in the development of NK-mediated cytotoxic T-cell–dependent antitumoral immune responses. The complement pathway could therefore be a potent therapeutic target to improve NK-dependent antitumoral immune responses in patients with cancer. Cancer Immunol Res; 2(3); 200–6. ©2013 AACR.